Nature Communications (Aug 2016)

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

  • Joonil Jung,
  • Joon Sang Lee,
  • Mark A. Dickson,
  • Gary K. Schwartz,
  • Axel Le Cesne,
  • Andrea Varga,
  • Rastilav Bahleda,
  • Andrew J. Wagner,
  • Edwin Choy,
  • Maja J. de Jonge,
  • Madelyn Light,
  • Steve Rowley,
  • Sandrine Macé,
  • James Watters

DOI
https://doi.org/10.1038/ncomms12609
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 7

Abstract

Read online

Pre-clinical studies have shown that TP53 mutations can account for acquired resistance to HDM2 antagonists. This study provides clinical evidence for the emergence of TP53mutations in circulating cell-free DNA, seen in 5 out of 20 de-differentiated liposarcoma patients treated with an HDM2 antagonist.